M onotherapy drug-eluting stents (DES) suppress neointimal proliferation and reduce the 1-year target lesion revascularization rate better than bare-metal stents but have other issues about safety and efficacy. 1,2 Inadequate endothelial strut coverage causes stent thrombosis requiring stringent dual-antiplatelet therapy. 3, 4 Late catch-up with cumulative increase in the target lesion revascularization rate seems inevitable for most monotherapy DES. 5 Accelerated Background-Current monotherapy drug-eluting stents are associated with impaired healing, neoatherosclerosis, and late stent thrombosis. The healing profile and neointimal transformation of the first dual-therapy endothelial progenitor cellcapturing sirolimus-eluting stent are unknown. Methods and Results-In this prospective, single-center study, 61 patients treated with the Combo stent had optical coherence tomography at baseline, early follow-up (4 monthly groups in a 1:2:2:1 ratio from 2 to 5 months), 9 months, and 24 months. Optical coherence tomography early strut coverage increased from 77.1% to 92.5% to 92.7% to 94.9% between 2 and 5 months. At 9 months, the major adverse cardiac event rate was 1.64%, and angiographic in-stent late loss was 0.24 mm (0.08-0.40). The 36-month major adverse cardiac event rate was 3.3%. From 9 to 24 months, neointimal regression was confirmed by optical coherence tomography: neointimal thickness (median [first quartile and third quartile]), 0.14 mm (0.08 and 0.21) versus 0.12 mm (0.07 and 0.19), P<0.001; neointimal volume, 29.9 mm 3 (22.1 and 43.2) versus 26.2 mm 3 (19.6 and 35.8), P=0.003; and percent neointimal volume, 17.8% (12.2 and 21.2) versus 15.7% (11.2 and 19.4), P=0.01. No definite or probable late stent thrombosis was recorded. Conclusions-With additional endothelial progenitor cell-capturing technology, the Combo stent exhibits a unique late neointimal regression (from 9 to 24 months) that has not been reported in any drug-eluting stents, translating into good 36-month clinical results with minimal restenosis and no late stent thrombosis. This is the first study testing the concept of using a longitudinal sequential optical coherence tomography protocol to continuously document early healing profile and late neointimal transformation, predicting long-term outcomes of a new novel stent platform. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifiers: NCT01274234, NCT01756807, and NCT02263313. (Circ Cardiovasc Interv. 2016;9:e003469.
The EGO-Combo Study neoatherosclerosis is common after DES implantation. 6, 7 To combat these, newer technologies have been developed.
Technology to capture endothelial progenitor cells with an anti-CD34 antibody coating has been developed as a radically different approach to promote vessel healing. [8] [9] [10] This technology has been combined with an abluminal sirolimus-eluting coating composed of a biodegradable polymer to form a new DES platform, the Combo stent (OrbusNeich Medical, Fort Lauderdale, FL). Sirolimus release (5 µg/mm) is completed in 30 days, and the biodegradable polymer disappears within 90 days. This dualtherapy approach aims for neointimal suppression while retaining the endothelial progenitor cell-capturing prohealing benefits enabling rapid endothelialization. [11] [12] [13] We have used a vigorous imaging protocol (longitudinal sequential optical coherence tomography [OCT] assessments) to evaluate this new Combo platform by monitoring its healing profile and neointimal transformation, hoping to predict its long-term outcomes.
Methods

Study Design
The EGO-Combo (OCT Evaluation of Healing of Combo Stent) study was a prospective, early phase-1 type, open-label (blinded analyses), single-arm, single-center study. The primary end point was OCT strut coverage (healing) at various time points; all OCT neointimal metrics and morphologies and all clinical events were recorded with extended protocols to 36 months. Clinical end points were all major adverse cardiac events at 3 years, including cardiac death, myocardial infarction, stent thrombosis, and target vessel revascularization. This study was not powered for clinical end points. All patients aged 18 years requiring stent treatment were eligible. Exclusion criteria included patients with ST-segment-elevation myocardial infarction, complex multivessel disease, and renal insufficiency with increased risk of contrast overload from repeated OCT examinations. The study protocols received full ethics committee approval (ClinicalTrials. gov identifiers: NCT01274234, NCT01756807, and NCT02263313); written informed consent was obtained for all patients.
Four longitudinal sequential OCT assessments were scheduled for each patient over 24 months (Figure 1 ). OCT at baseline was performed to optimize stent implantation and repeated at early follow-up (2-5 months) in 4 randomly assigned monthly groups in a 1:2:2:1 ratio for establishment of the early healing profile (percentage strut coverage and coverage categories), at 9 months for neointima metrics and morphology, and finally at 24 months for tracking neointimal transformation and late catch-up. All patients received 9-to 12-month dual-antiplatelet therapy. All clinical event adjudications, quantitative coronary angiography analyses, and OCT analyses were undertaken by independent core laboratories (Cardiovascular Research Foundation, New York, NY).
Image Acquisition, Image and Data Analysis, and Definitions
Quantitative coronary angiography analysis was performed using QAngio XA version 7.2.34.0 (Medis Medical Imaging Systems, Leiden, The Netherlands) using standard methods. 14 All OCT images were collected with the C7-XR OCT Intravascular Imaging System (St. Jude Medical, St. Paul, MN) and Dragonfly imaging catheter (St. Jude Medical) at a pullback rate of 5 frames/mm (0.2 mm slice thickness) and a pullback length of 54 mm using 14 to 16 mL of contrast. All OCT analyses were performed in a blinded fashion to the time points and clinical details, using LightLab Imaging Offline Review Workstation, software version C.0.4 (St. Jude Medical). Qualitative strut coverage analyses were done for all individual struts in all frames, whereas all other OCT metrics were analyzed at a 1-mm sampling interval (1 of every 5 frames) as recommended. 15, 16 A stringent prespecified 6-category classification was used to ensure consistency of visual assessment of early strut coverage ( Figure 2 ); categories D, E, and F represent covered struts. Stent area and lumen area were identified, and neointimal thickness and neointimal area were determined. Malapposition was defined when the malapposed distance was >104 μm (100 μm strut thickness+4 μm polymer thickness). Total neointimal and stent volumes were calculated using Simpson rule, and percent neointimal volume was calculated by neointimal volume divided by stent volume×100.
Extrastent lumen area was defined as the sum of all lumen areas external to the stent lumen, including all evagination (positive remodeling) areas and malapposed areas. 17 An extrastent lumen area was considered major if the maximum depth was ≥10% of the stent diameter. The morphological appearance of neointima within a stent was described if the neointima was large enough to be evaluable (mean neointimal thickness >100 µm and length ≥3 mm) and was labeled as (1) homogeneous with a uniform signal-rich neointima without focal variation or attenuation, (2) heterogeneous with focally varying backscattering pattern, and (3) layered with a signal-rich inner layer and a signal-poor abluminal layer. Peristrut low-intensity area was defined as a homogeneously signal-poor region around stent struts without signal attenuation. 18, 19 Neoatherosclerosis was defined as the presence of lipid or calcified plaque within the neointima. 6, 7 
Statistical Methods
Continuous variables were presented as mean and SD, if the values were normally distributed; otherwise, they were presented as median and first and third quartiles.
Changes in continuous OCT variables across follow-up time points were analyzed using 2 separate models. Both of the following models were created using PROC MIXED in SAS using restricted maximum likelihood estimation. The first model was for the 2-to 5-month OCT assessment time points when all subjects were studied once; a 1 by 4 completely randomized analysis of variance model was used. The effect of time was a between-subjects effect. Clustering of lesions within patients was accounted for by specifying a compound symmetrical covariance structure in a hierarchical mixed model with patient as a random effect. Pair-wise post hoc comparisons were
WHAT IS KNOWN
• Monotherapy drug-eluting stent suppresses neointimal proliferation at the expense of delayed endothelialization. Late catch-up phenomenon and accelerated neoatherosclerosis may occur and lead to late stent failure.
• Use of a dual-therapy technology stent with endothelial progenitor cell capture and an abluminal sirolimus-eluting coating was shown to be noninferior to a paclitaxel-eluting stent with respect to angiographic late loss at 9 months and clinical outcome at 1 year.
WHAT THIS STUDY ADDS
• Longitudinal sequential optical coherence tomography follow-up of a cohort of Combo stent patients demonstrated neointimal regression from 9 to 24 months that was associated with good clinical outcomes.
• Serial assessment by high resolution optical coherence tomography imaging is an excellent tool to examine neointimal transformation for future stent platforms. made using the Tukey method. A second model was used to evaluate differences between the last 2 time points (9 and 24 months). These analyses were done by treating time as a within subjects (repeatedmeasures) effect. Clustering of lesions within subjects was accounted for in the mixed model as described for the between-subjects model. This same model was used to compare the within subjects changes in the quantitative coronary angiography data.
The measurements of neointimal thickness on individual struts within a lesion could not be matched among different time points. Therefore, comparison of the changes in these strut-level Definitely uncovered-strut not covered by tissue, and both sides appear square (A); uncovered with abnormal in-stent tissue-strut covered by irregular tissue or fibrin, and both sides appear square (B); partially uncovered-strut partially covered by tissue but only 1 side has a smooth continuous shoulder (C); covered (protruding)-strut covered by thin continuous tissue on both sides but still extending into the lumen (D); covered (embedded)-strut covered by continuous tissue or neointima and not interrupting the smooth lumen contour (E); and covered (proliferative)-strut covered with excessive growth of neointima with thickness of >0.3 mm (F).
measurements was made as a between-subject effect for both the models (between 2, 3, 4, and 5 months and from 9 to 24 months).
Both the models included random effects that accounted for the clustering of struts within lesions and lesions within patients. The change in percentage of uncovered struts as a function of early follow-up (2-5 months, included in the model as the log of days since stent implantation) was modeled using a mixed effect model that controlled for the clustering of multiple lesions within patients using an unstructured covariance structure. Intraobserver and interobserver variability for the diagnosis of strut coverage, extrastent lumen area, peristrut low-density area, and neointimal morphology was assessed using Cohen κ statistics. A 2-sided P value of <0.05 was considered statistically significant. The most statistical analyses were performed using SAS version 9.2 (SAS Institute Inc, Cary, NC). The mixed effect model and conditional R 2 were computed using MuMIn package version 1.15.6 in R version 3.2.2 (R Foundation, Vienna, Austria).
Results
A total of 61 patients were enrolled with 74 lesions treated by 88 Combo stents. Baseline patient characteristics, lesion characteristics, and angiographic results are summarized in Tables 1 through 3, respectively. Clinical events are shown in Figure 1 .
Angiographic and Clinical Findings
All angiograms before 9 months were recorded by an old x-ray systems composed of image intensifier and camera tube (Integris CV9, Philips Healthcare, Andover, MA); all systems were replaced by flat panel systems (Allura Xper F10/10, Philips Healthcare) at 24 months. Systemic changes in all quantitative coronary angiography parameters were found, rendering valid interpretation between 9 and 24 months difficult. Thus, only baseline and 9-month results were compared (Table 3) . At 9-month follow-up, only 1 patient had angiographic restenosis requiring revascularization by simple ballooning, thus the target lesion revascularization rate was 1.64% (1/61). At 22 months, an elderly patient experiencing recurrent chest pain after many days without seeking medical advice died with documented ventricular fibrillation (cardiac death). At 24 months, 1 patient was lost to follow-up (emigrated). All of the remaining 58 patients were asymptomatic, and 17 patients declined further OCT follow-up, thus the 24-month OCT follow-up rate was 68.3% (41/60). The overall major adverse cardiac event rate was 3.3%
(2/61) beyond 36 months. No Academic Research Consortium definite or probable late stent thrombosis was recorded.
OCT Findings
Results of 4 longitudinal sequential OCT assessments from 2 to 24 months are shown in Table 4 ; Table I and Figure I OCT intra-and interobserver variability were in excellent concordance (κ=0.95 and κ=0.92, respectively) for the 6 categories of early strut coverage and in complete agreement for extrastent lumen area, peristrut low-density area, and neointimal morphology assessment.
Early-phase healing is shown in Figure 3 . Coverage increased progressively from 77.1% to 92.5% to 92.7% to 94.9% (median) from 2 to 5 months; coverage was close to 100% by 9 months (Table 4 ). No late-acquired noncoverage of struts was observed. Sequential changes in neointimal thickness and percentage neointimal volume are presented in the cumulative percentage charts in Figure 4 . Progressive right shifting from early to 9 months has indicated neointimal proliferation, yet by 24 months, instead of further right shifting as anticipated for late catch-up, an incidental discovery of reverse shifting to the left was observed, indicating neointimal regression. Further analyses confirmed the significant late neointimal regression at strut-level neointimal thickness, frame-level neointimal area, stent-level neointima volume, and percent neointima volume (refer to Figure 4 ; Figure I in the Data Supplement for absolute values).
Despite baseline OCT optimization, early follow-up (2-5 months) showed major extrastent lumen area as defined above in 31.1% (23/74) of lesions in 20 patients. Such extrastent lumen areas significantly disappeared in just 9 months, with no further late-acquired positive remodeling observed ( Figure 5 top), representing excellent healing. Malapposed struts were found only in 4 patients at 9 months of follow-up (median 0.08% of total struts) and in 1 patient at 24 months of follow-up.
Changes in morphological appearance of the neointima are shown in the lower panel of Figure 5 . Thirty-three lesions in the early phases had too thin neointima (<100 μm) to be Values are n (%) or mean±SD. evaluated. Progressive increases in homogeneous neointima (conversion from heterogenous and layered neointima) with a reduction in peristrut low-density area were documented over time. Cholesterol crystals appeared in 1 patient; otherwise there was no lipidic plaque or neoatherosclerosis observed. Only at 2 months were 2 small, platelet-rich thrombi (diameter 0.28 mm and 0.6 mm) detected by OCT in 2 patients; both disappeared in later follow-up phases. No other thrombotic event was recorded.
Discussion
Monotherapy DES had late stent failure that is apparent only after years of implantation, 1-7 and the prolonged use of dual-antiplatelet therapy is associated with an increased risk of bleeding. [20] [21] [22] Newer DES with various technologies are being developed. 23, 24 A structured systematic evaluation protocol for a DES from early healing to late neointimal transformation, potentially predicting long-term outcomes, has never been described partly because of the lack of high resolution in vivo imaging technology until the availability of frequency-domain OCT. 15, 16 We attempted to bridge this scientific gap by first designing and testing the concept of using a novel imaging protocol (longitudinal sequential OCT assessments) to evaluate a new stent platform claimed to be prohealing with a dual-therapy approach, the Combo stent, hoping that such a protocol could help predict outcomes earlier for any new stent platforms, rather than having to wait many years for the positive or adverse results to surface. Impaired strut endothelialization is the most powerful histological predictor for stent thrombosis. 25 Strut coverage mitigates stent thrombosis, but substantial neointimal coverage will take much longer for DES. 26, 27 The capacity of OCT to detect the various degrees of strut coverage in vivo is comparable to that of histology under light and electron microscopy. 28 Despite its high axial resolution of 10 to 15 μm (still several cell layers thick), OCT is not able to detect a single endothelial cell layer and therefore assess true endothelialization. Therefore, the presence of detectable true strut coverage (excluding abnormal in-stent tissue as discussed below) under a stringent classification by OCT could represent a surrogate marker for potential stent coverage by endothelial cells. The development of our stringent 6-category OCT coverage classification ( Figure 2 ) contributes to a more accurate visual quantitation to distinguish between covered and uncovered struts in a prespecified manner. Besides, stent healing is a complex process involving various cell types and OCT-derived neointimal thickness/volume assess the amount and morphology of in-stent tissue growth. Therefore, true poststenting histological transformation cannot be evaluated precisely.
Caution must be exercised about interpretation of strut coverage in early stages after stent implantation, as prolapsed tissue, fibrin deposition, and thrombus formation may all be mistakenly interpreted as true neointimal coverage. Such abnormal in-stent tissues (as shown in Figure 2 ) are not true coverage and are often evident in baseline OCT pullbacks right after stenting. Therefore, it is mandatory to have longitudinal sequential assessments to document true neointimal coverage and healing, which should include a progressive increase in percent strut coverage with no reversal to uncovered struts from previously covered sites, no development of late thrombus, and true documentation of maturing homogeneous neointima without development of late stent failure, as presented in Compared with angiographic quantitative coronary analysis, which gives just one set of binary restenosis figures per lesion per time point, OCT has a much higher accuracy and sampling capacity that even a relatively small patient sample would be sufficient to reveal the neointimal behavior evolving around a new stent. Despite only 61 patients at 4 different time points, the absolute numbers of OCT frame and strut counts were huge, as listed in Table 4 . Combined with the high clinical and OCT follow-up rates (Figure 1 ), the study data should reflect the true and complete evolution of this new Combo stent and its long-term clinical results as predicted.
The findings of a 9-month angiographic late loss of 0.24 mm and a durable target lesion revascularization rate of just 1.64% (9-36 months) support the antiproliferative efficacy of the Combo stent as a DES. 12 What remains to be determined is how much this dual-therapy approach would be different compared with conventional monotherapy DES. No other DES studies have reported early sequential OCT Figure 3 ); therefore, it is impossible to compare our findings with previous studies. Rapid healing was observed for Combo, and only 5 months of dual-antiplatelet therapy could be recommended with almost 100% coverage predicted by 150 days. The only objective of DES development to supplant baremetal stents is to suppress restenosis; however, late catch-up leading to cumulative restenosis seems to be a universal phenomenon for all monotherapy DES, despite the initial claims of little late loss in the first 6 to 9 months, with cumulative increases in target lesion revascularization rates reported during the next 5 years. 7 Thus, current monotherapy DES may only deliver palliative treatment and postpone restenosis at the expense of many other adverse side effects. One interesting finding of this new stent platform with a dual-therapy approach is the incidental discovery of significant OCT neointimal regression from 9 to 24 months ( Figure 4 ; Figure I in the Data Supplement). Although this phenomenon has been suggested in the bare-metal stents era, 9 such unique late neointimal regression has never been documented in any monotherapy DES. Such regression is accompanied by no late catch-up phenomenon, leading to good 36-month clinical results with no further increase in late target lesion revascularization. Further studies are needed to evaluate whether this neointimal regression phenomenon can transform into true long-term clinical benefit. Practically, all published DES studies with OCT just report on only 1 time point. 17, [29] [30] [31] The Combo stent is the only study with 4 longitudinal sequential OCT assessments, documenting all OCT parameters that could influence outcomes as reported in the literature. Development of extrastent lumen area represents an adverse vascular response after DES implantation. 17 Peristrut low-density area may represent the presence of fibrinoid and proteoglycans and is associated with inflammation and neointimal proliferation after stenting. 18, 19 Findings of reduction in extrastent lumen area, peristrut low-density area, and neointimal heterogeneity without development of late stent failure further support the potential benefits of the endothelial progenitor cell-capturing technology in combination with sirolimus elution. Such precise longitudinal follow-up documenting all temporal neointimal changes by a high resolution imaging technology have never been reported for any DES. These favorable OCT findings in this particular Combo stent could translate into favorable clinical outcomes, as reflected by the excellent target lesion revascularization rate (1.64%) and major adverse cardiac event rate (3.3%) beyond 36 months.
This study has several limitations. First, in this original design as a proof-of-concept study, this longitudinal sequential OCT protocol requiring 4 OCT pullbacks was limited to just a single arm for obvious safety and feasibility reasons. Therefore, this study is mainly observational and a comparator stent as control would have improved the study significantly. Second, as aforementioned, strut coverage and neointimal thickness/volume detected by OCT needs to be interpreted with caution and we adopt this stringent protocol to prospectively assess poststenting neointimal behavior in multiple time points. However, true predictive values of longitudinal sequential OCT assessments on late outcomes of DES require further validation by larger scale, randomized, controlled trial comparing DES of different designs. 
Conclusions
This endothelial progenitor cell-capturing technology with sirolimus elution of the Combo stent seems to deliver good long-term clinical results with significant late neointimal regression. Further studies are required to evaluate whether this can transform into true long-term clinical benefit. The longitudinal sequential OCT assessment protocol aiming to predict long-term clinical results seems to be a novel approach and could be used to evaluate future new DES platforms. , different categories of uncovered struts (arrow heads) are shown, whereas a heterogeneous neointima is present in B. At 9 months, both C and D exhibit well-covered struts, and in D the change of a heterogeneous neointima to a more homogeneous one, still with peristrut low-intensity areas (PLIA) at 11 to 3 o'clock. By 24 months, conversion to a homogeneous neointima is evident with reduction of neointimal thickness (F) compared with 9 months. Such progressive transformation to mature neointima with late neointimal regression and lumen gain was observed in the majority of cases treated by Combo stents, which translated into excellent clinical results beyond 36 months.
